Clinical Trial Update: Treatment of SARS Caused by COVID-19 With Ruxolitinib [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating ruxolitinib for treatment of COVID-19 related SARS-CoV-2 infection has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syndrome Coronavirus 2

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Grupo Cooperativo de Hemopatías Malignas | Conditions: COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2 | Phase 1, Phase 2 | Status: COMPLETED